# A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

> **NCT02748967** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ExPEC4V
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02748967
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748967, "A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02748967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*